Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The interplay of behavioral therapies, pharmacological treatments and psychiatric adverse events among Youth with Autism Spectrum Disorders

Award Number: R01HS029003
ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY
OPDIV: AHRQ
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

The interplay of behavioral therapies, pharmacological treatments and psychiatric adverse events among Youth with Autism Spectrum Disorders - ABSTRACT Autism Spectrum Disorder (ASD) is a lifelong, neurodevelopmental disorder with significant consequences for individuals and their families. Over 95% of individuals with ASD have at least one comorbid psychiatric, neurologic, or physical health condition. Many also struggle with other developmental challenges such as intellectual disabilities and/or complex communication needs and often receive inadequate care. These unmet needs, which often begin in childhood, can have negative impacts on the health and well-being of those with ASD through their lives. The incidence rates of adverse outcomes have steadily increased for youth with ASD over the last decade. While consistent management of mental health and other comorbid conditions might reduce episodes of emergencies, the heterogeneity of ASD and health disparities resulting from race/ethnicity, gender, and/or socioeconomic status (SES) potentially impede the effectiveness of evidence- based treatments for ASD in the “real world”. In addition, the increasing practice of excessive polypharmacy of psychotropic medication is likely to have negative impact on utilization and effectiveness of non- pharmacological treatments, though little is known about its specific effect on uptake as well as, intensity and duration of behavioral therapies. The COVID-19 pandemic has increased stress on individuals with mental health illnesses, and, subsequently, incidence of psychiatric crises. Understanding treatment utilization patterns and variations across demographic, geographic and socioeconomic factors will provide guidance to improve the efficiency of health care delivery and quality of health services for individuals with ASD. Leveraging large, national, longitudinally constructed Medicaid claims databases (2008-2022), we will examine the interplay between polypharmacy of psychotropic medications and key ASD behavioral therapies among youth aged 5-26 with ASD and evaluate their impact on preventing behavioral health crises. In particular, we will (1) examine the trends and multi-level factors associated with utilization and quality of behavioral health and pharmacological treatments among youth with ASD; (2) examine the trends and health disparities in the rates of psychiatric adverse events among youth with ASD; (3) examine the impact of quality of behavioral health treatments and their interplay with polypharmacy on psychiatric adverse events among youth with ASD. The proposed study will provide a comprehensive assessment of the quality of ASD-related treatments and services in a real-world setting and shed light on disparities in service use, quality of care, and health outcomes, particularly in regards to the risk of behavioral health crises among youth with ASD. This information will be valuable to families exploring treatment options, as well as to providers in determining treatment options to maximize benefit. Identifying barriers to accessing services and implementation of evidence-based practice will help guide policies at the payer, state, and national levels.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	PENNSYLVANIA STATE UNIVERSITY	500 UNIVERSITY DRIVE	HERSHEY	PA	17033	DAUPHIN	USA	Research on Healthcare Costs, Quality and Outcomes	000	3	2/6/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $386,704 )
2025	2025	PENNSYLVANIA STATE UNIVERSITY	500 UNIVERSITY DRIVE	HERSHEY	PA	17033	DAUPHIN	USA	Research on Healthcare Costs, Quality and Outcomes	000	3	3/27/2025	NON-COMPETING CONTINUATION	$386,704
														Subtotal = $386,704

Issue Date FY: 2024 ( Subtotal = $386,704 )
2024	2024	PENNSYLVANIA STATE UNIVERSITY	500 UNIVERSITY DRIVE	HERSHEY	PA	17033	DAUPHIN	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	3/15/2024	NON-COMPETING CONTINUATION	$386,704
														Subtotal = $386,704

Issue Date FY: 2023 ( Subtotal = $382,554 )
2023	2023	PENNSYLVANIA STATE UNIVERSITY	500 UNIVERSITY DRIVE	HERSHEY	PA	17033	DAUPHIN	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	3/15/2023	NEW	$382,554
														Subtotal = $382,554

Grand Total All Awards = $1,155,962

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The interplay of behavioral therapies, pharmacological treatments and psychiatric adverse events among Youth with Autism Spectrum Disorders

Award Number: R01HS029003

ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY

OPDIV: AHRQ

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer